Targeting distribution of anti-CD19(Fab)-LDM:a new anti-lymphoma drug
10.3969/j.issn.1001-1978.2014.07.008
- VernacularTitle:新型抗淋巴瘤药物anti-CD19（Fab）-LDM的靶向分布研究
- Author:
Yuzheng SHI
;
Hongqin LIU
;
Linlin JIANG
;
Ming YANG
;
Dongmei FAN
;
Hao QU
;
Lin SHI
;
Chuan SHI
;
Chunling FENG
;
Yun LIU
;
Dongsheng XIONG
;
Xiaolong LIAO
- Publication Type:Journal Article
- Keywords:
lymphoma;
anti-CD19(Fab);
LDP;
Cy5 labeled;
xenograft model;
targeting distribution
- From:
Chinese Pharmacological Bulletin
2014;(7):917-920,921
- CountryChina
- Language:Chinese
-
Abstract:
Aim To study targeting capability of anti-CD19 (Fab)-LDMto CD19 +B lymphoma cells in vi-vo and in vitro.Methods Flow cytometry was em-ployed to determine the affinity of Cy5 labeled anti-CD19 (Fab)-LDP to human lymphoma Raji cells.And the optical imaging system was used to analyze the dis-tribution of Cy5-anti-CD19 (Fab )-LDP in lymphoma-transplanted xenograft nude mice in vivo.Results The results of flow cytometry demonstrated that Cy5-an-ti-CD19(Fab)-LDP had remarkable affinity with lym-phoma Raji cells;Raji lymphoma xenograft model was established successfully in nude mice and in vivo fluo-rescence imaging analysis indicated that the antibody-drug conjugates could specially be localized in the tar-get tumor.Conclusion The experiments in vivo and vitro confirm that anti-CD19 (Fab)-LDP has remarka-ble affinity to targeting CD19 +lymphoma cells,and the antibody drugs anti-CD19 (Fab )-LDP have the probability to be new drugs for the treatment of malig-nant lymphoma.
